Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVAMUNE booster vaccination 2 years after prior IMVAMUNE (former POX-MVA-005 vaccinees)
2007-006297-28Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- May 2008
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of JYNNEOS in smallpox (2 arms), sponsored by Bavarian Nordic. Primary endpoints: Primary immunogenicity endpoint and Primary safety endpoint. Started May 2008; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on 2007-006297-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006297-28.